Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
Fundación Pública Andaluza para la investigación Biosanitaria de Andalucía oriental (FIBAO)
RED RED
Polymorphisms to predict or predicting the response to antiviral treatment
A research group Public Health System of Andalusia has developed a method of
obtaining useful data to predict or forecast the response to treatment with
pegylated interferon plus ribavirin in patients with chronic hepatitis C genotype 1.
 
The hepatitis C virus (HCV) is one of the most common causes of chronic viral hepatitis, liver cirrhosis and hepatocellular carcinoma, the most common indication for liver
transplantation.
Researchers have identified a number of mutations that are useful in determining the response to antiviral therapy with pegylated interferon plus ribavirin in patients with chronic
hepatitis C genotype 1.
This research can be used in the prediction or forecast of nonSVR
in patients with HCV.
 
 
Related links:
 
 
Permalink: http://www.mercadosbiotecnologicos.com/?iid=77&own=2&itid=3&lan=en
 
Search